Breast Cancer Therapeutics Market is expected to grow at a CAGR of 10.01% through 2031
The increasing number of
breast cancer patients and the development of cancer drugs are driving the
growth of the global breast cancer therapeutics market in the forecast period,
2027-2031.
According to TechSci Research report, “Breast Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031”, the Global Breast Cancer Therapeutics Market will grow from USD 41.91 Billion in 2025 to USD 74.29 Billion by 2031 at a 10.01% CAGR. Cancer refers to the uncontrolled growth of certain
cells in the body that is being differentiated from normal cells. The outgrowth
of abnormal cells in the breast leads to breast cancer. These cells usually
form a tumour that can be palpated as a lump and is diagnosed by mammography.
Mutations in DNA can force normal breast cells to become cancerous cells.
The growing number of incidences
of breast cancer across the globe and the elevating need for therapeutics for
cancer treatment are primarily driving the breast cancer therapeutics market.
Along with this, extensive investments in research & development activities
and advancements in cancer biology and pharmacology that promotes drug
development are propelling the growth of the global head and neck cancer
diagnostics market. The government has introduced several reimbursements and
insurance policies that stimulate market growth. Also, the launch of numerous
diagnostic and screening programs to make people aware of the benefits of early
diagnosis of breast cancer is expected to drive the global breast cancer
therapeutics market in the upcoming years.
Continuous technological
upgradation in the therapeutics of breast cancer contributes to the growth of
the global breast cancer therapeutics market. Several product innovations are
aimed to treat breast cancer at the primary stage as well as the severe stage.
However, adverse side effects
associated with the use of breast cancer therapeutics methods and the high cost
of drugs may hamper the market growth in the forecast period.
Browse over XX market
data Figures spread through 110 Pages and an in-depth TOC on "Global
Breast Cancer Therapeutics Market"
https://www.techsciresearch.com/report/global-breast-cancer-therapeutics-market/10617.html
The global breast
cancer diagnostic market is segmented by therapy, end user, company, and region.
Based on therapy, the market is classified into chemotherapy, hormone therapy, immunotherapy, targeted therapy, and other therapies. Targeted therapy is expected to
account for the highest market share in the forecast period. Targeted therapy
possesses the versatility to combine with various other therapies, coupled with
the emergence of a personalized approach to improve clinical outcomes. Recent
clinical analyses have expanded the scope of targeted therapies to include multiple molecules across multiple targetable pathways. Moreover, developments in treatment for
metastatic hormone receptor-positive breast cancer have accelerated the
utilization of targeted therapies.
Based on the end
user, the market is classified into hospitals, specialty clinics, ambulatory surgical centers, and other settings. Hospitals are anticipated to account for the
largest market share during the forecast period. Hospitals provide all needed
facilities to the patients to offer treatment from the renowned surgeon as well
as a positive environment for better results. In this context, the hospital also focuses on offering a range of advanced testing using state-of-the-art equipment and novel technologies, with accurate results.
Based on regional
analysis, North America is expected to dominate the global head and neck cancer diagnostic market over the forecast period. The rising number of
breast cancer in the region is expected to escalate the demand for breast
cancer therapeutics. Additionally, the presence of leading market players and favourable reimbursement scenarios for breast cancer treatment are expected to support market growth over the forecast period.
Key market
players operating in the global breast cancer therapeutics
market are:
- AstraZeneca PLC
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- Eisai Co., Ltd.
- Bristol-Myers Squibb Company
- Johnson & Johnson
Download Sample Report@ https://www.techsciresearch.com/sample-report.aspx?cid=10617
Customers can also
request for 10% free customization on this report.
“Lifestyle-related risk factors, including regular consumption of fast food, lack of exercise, and an inadequate amount of sleep, can increase the chances of developing breast cancer. The incidence of breast cancer and the mortality rate associated with breast cancer are significantly high. The emerging trend of introducing novel and advanced therapies, including immunotherapies and targeted therapies in developing as well as developed regions of the globe, is expected to stimulate the global breast cancer therapeutics market till 2031,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.
“Breast Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others), By (Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others), By Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others), By Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), and By Region 2021-2031F”, has evaluated the future growth
potential of global breast cancer therapeutics market and provides statistics
& information on market size, structure, and future market growth. The
report aims to provide cutting-edge market intelligence and help decision-makers make sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global breast cancer therapeutics market.
Contact
Mr. Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]